Global Influenza Medications Market Growth, Size, Trends Analysis - By Type, By Distribution Channel - Regional Outlook, Competitive Strategies and Segment Forecast to 2034

Description

Influenza Medications Market Introduction and Overview

According to SPER market research, 'Global Influenza Medications Market Size- By Type, By Distribution Channel - Regional Outlook, Competitive Strategies and Segment Forecast to 2034' state that the Global Influenza Medications Market is predicted to reach 2020.5 million by 2034 with a CAGR of 7.32%.

Influenza medications refer to pharmaceuticals that are utilized for either the prevention or treatment of infections that are instigated by influenza viruses. These drugs assist in diminishing both the severity and duration of symptoms associated with the flu, which may include fever, cough, bodily aches, and fatigue. The primary categories consist of antiviral agents such as oseltamivir (Tamiflu), zanamivir (Relenza), peramivir (Rapivab), and baloxavir marboxil (Xofluza).

Restraints: The swift evolution of influenza viruses may persist as an obstacle, as it has the potential to decrease the efficacy of current medications while necessitating ongoing revisions of treatment guidelines. Additionally, the accessibility and dependency on seasonal influenza vaccinations will further diminish the need for antiviral medications. Challenges posed by regulatory requirements and complex approval pathways can hinder the timely launch of innovative therapies.

Scope of the report:

Report Metric Details

Market size available for years 2021-2034

Base year considered 2024

Forecast period 2025-2034

Segments covered By Type, By Distribution Channel

Regions covered North America, Latin America, Asia-Pacific, Europe, and Middle East & Africa

Companies Covered Biondvax, Daiichi Sankyo Company, Hoffmann-La Roche Ltd (Genentech USA, Inc), GlaxoSmithKline, Genentech USA, Inc, NATCO Pharma Limited, Novartis AG, Sanofi, Seqirus, Shionogi & Co, Ltd.

Global Influenza Medications Market Segmentation:

By Type: Based on the Type, Global Influenza Medications Market is segmented as; Antiviral Drugs, Antihistamines, Vaccines, Other.

By Distribution Channel: Based on the Distribution Channel, Global Influenza Medications Market is segmented as; Hospital Pharmacies, Retail Pharmacies, Online Pharmacies.

By Region: This research also includes data for North America, Latin America, Asia-Pacific, Europe, Middle East & Africa.

Product Code: PHAR2509

1. Introduction

1.1. Scope of the report
1.2. Market segment analysis

2. Research Methodology

2.1. Research data source
- 2.1.1. Secondary Data
- 2.1.2. Primary Data
- 2.1.3. SPERs internal database
- 2.1.4. Premium insight from KOLs
2.2. Market size estimation
- 2.2.1. Top-down and Bottom-up approach
2.3. Data triangulation

3. Executive Summary

4. Market Dynamics

4.1. Driver, Restraint, Opportunity and Challenges analysis
- 4.1.1. Drivers
- 4.1.2. Restraints
- 4.1.3. Opportunities
- 4.1.4. Challenges

5. Market variable and outlook

5.1. SWOT Analysis
- 5.1.1. Strengths
- 5.1.2. Weaknesses
- 5.1.3. Opportunities
- 5.1.4. Threats
5.2. PESTEL Analysis
- 5.2.1. Political Landscape
- 5.2.2. Economic Landscape
- 5.2.3. Social Landscape
- 5.2.4. Technological Landscape
- 5.2.5. Environmental Landscape
- 5.2.6. Legal Landscape
5.3. PORTERs Five Forces
- 5.3.1. Bargaining power of suppliers
- 5.3.2. Bargaining power of buyers
- 5.3.3. Threat of Substitute
- 5.3.4. Threat of new entrant
- 5.3.5. Competitive rivalry
5.4. Heat Map Analysis

6. Competitive Landscape

6.1. Global Influenza Medications Market Manufacturing Base Distribution, Sales Area, Product Type
6.2. Mergers & Acquisitions, Partnerships, Product Launch, and Collaboration in Global Influenza Medications Market

7. Global Influenza Medications Market, By Type (USD Million) 2021-2034

7.1. Antiviral Drugs
7.2. Antihistamines
7.3. Vaccines
7.4. Other

8. Global Influenza Medications Market, By Distribution Channel (USD Million) 2021-2034

8.1. Hospital Pharmacies
8.2. Retail Pharmacies
8.3. Online Pharmacies

9. Global Influenza Medications Market, (USD Million) 2021-2034

9.1. Global Influenza Medications Market Size and Market Share

10. Global Influenza Medications Market, By Region, (USD Million) 2021-2034

10.1. Asia-Pacific
- 10.1.1. Australia
- 10.1.2. China
- 10.1.3. India
- 10.1.4. Japan
- 10.1.5. South Korea
- 10.1.6. Rest of Asia-Pacific
10.2. Europe
- 10.2.1. France
- 10.2.2. Germany
- 10.2.3. Italy
- 10.2.4. Spain
- 10.2.5. United Kingdom
- 10.2.6. Rest of Europe
10.3. Middle East and Africa
- 10.3.1. Kingdom of Saudi Arabia
- 10.3.2. United Arab Emirates
- 10.3.3. Qatar
- 10.3.4. South Africa
- 10.3.5. Egypt
- 10.3.6. Morocco
- 10.3.7. Nigeria
- 10.3.8. Rest of Middle-East and Africa
10.4. North America
- 10.4.1. Canada
- 10.4.2. Mexico
- 10.4.3. United States
10.5. Latin America
- 10.5.1. Argentina
- 10.5.2. Brazil
- 10.5.3. Rest of Latin America

11. Company Profile

11.1. Biondvax
- 11.1.1. Company details
- 11.1.2. Financial outlook
- 11.1.3. Product summary
- 11.1.4. Recent developments
11.2. Daiichi Sankyo Company
- 11.2.1. Company details
- 11.2.2. Financial outlook
- 11.2.3. Product summary
- 11.2.4. Recent developments
11.3. Hoffmann-La Roche Ltd (Genentech USA, Inc)
- 11.3.1. Company details
- 11.3.2. Financial outlook
- 11.3.3. Product summary
- 11.3.4. Recent developments
11.4. GlaxoSmithKline
- 11.4.1. Company details
- 11.4.2. Financial outlook
- 11.4.3. Product summary
- 11.4.4. Recent developments
11.5. Genentech USA, Inc
- 11.5.1. Company details
- 11.5.2. Financial outlook
- 11.5.3. Product summary
- 11.5.4. Recent developments
11.6. NATCO Pharma Limited
- 11.6.1. Company details
- 11.6.2. Financial outlook
- 11.6.3. Product summary
- 11.6.4. Recent developments
11.7. Novartis AG
- 11.7.1. Company details
- 11.7.2. Financial outlook
- 11.7.3. Product summary
- 11.7.4. Recent developments
11.8. Sanofi
- 11.8.1. Company details
- 11.8.2. Financial outlook
- 11.8.3. Product summary
- 11.8.4. Recent developments
11.9. Seqirus
- 11.9.1. Company details
- 11.9.2. Financial outlook
- 11.9.3. Product summary
- 11.9.4. Recent developments
11.10. Shionogi & Co., Ltd
- 11.10.1. Company details
- 11.10.2. Financial outlook
- 11.10.3. Product summary
- 11.10.4. Recent developments
11.11. Others